1Research on antecedent configuration of knowledge advantages for innovative performance of pharmaceutical manufacturing industry under technology-organization-environment frameworkZHU Wang-wang, TAO Qun-shan, TAO Shi-qi, FU Rui961-9702Construction of the benefit distribution mechanism about pharmaceutical industrial technology innovation strategic alliance based on bargaining gameHUA Dong, WANG Yan-hui971-9773Exploration and inspiration of orphan drug registration systems at home and abroadFANG Zhong-jian, LIN Le-ting, WANG Cai-yi, SHEN Chen, ZHANG Liang, WANG Ying-xia, ZHU Si-qi, SHAO Rong, SHAO Ming-li, FAN Yu-lu978-9834An introduction to the determination path and management model of chemical initial products in JapanLIU Yi-lin, NING Li-li, LI Fang, AN Na, HA Li-li, GUO Zhi-xin984-9875Current situation and prospect of immunoglobulin A as therapeutic drugsSHI Jiang-long, SUN Wen-ze, PAN Yong-bing988-9956Progress in organoid co-culture modelsFU Guan-shuang, CHEN Hui-ling, YANG Tian-li, CAI Yun996-10017Research progress in the chemical composition,pharmacological effects,and quality control of Omphalia LapidescensYANG Yang, WANG Jue, YANG Hui-ying, YANG Rui, XIAO Xin-yue1002-10088Matrix effects in liquid chromatography-mass spectrometry analysis techniquesFENG Yuan-yuan, TIAN Ye, YIN Li-hui, NING Bao-ming1009-10209The role and regulation mechanism of macrophage polarization in liver fibrosis and the intervention of traditional Chinese medicinePENG Wang-xia, LU Hua-guan, XIE Xin, LIU Jian-jun1021-103110Optimization of the formulation of IMP-RH60/mPEG-PLLA micelles by central composite design-response surface methodology and its evaluation in vitroLI Qiu-xiang, DONG Wei, ZHOU Ai-xian, ZHAO Guo-wei, LU Yong-feng, SHI Shang, LIANG Xin-li1032-104211Preparation and in vitro evaluation of three nicotine transdermal vesiclesWANG Hui, SHAO Qing, ZHANG Yan, ZHANG Ling, WU Qiang-ju1043-104912Optimization of acid hydrolysis conditions for an adjuvant polysaccharide PCP-Ⅱ from Poria cocos,isolation of hydrolysis products,and determination of their physic-chemical propertiesGU Jia-nan, LIU Gui-xin, MA Hao, SHAN Jun-jie1050-106113Calibration of the proposed 2nd batch of national standard reference for lysine vasopressinWU Yan-lin, GUO Long-jing, YANG Ze-an, GAO Hua, CAO Chun-ran, ZENG Ya-li, MENG Chang-hong, LU Yi-hong, TANG Li-ming, HANG Ai, KUANG Rong, MENG Hong, ZHU Min-ying, XIA Xing-hui, YE Fei, ZHANG Yuan1062-106714Analysis of adverse reactions and influencing factors of programmed death receptor 1 inhibitors in the treatment of malignant melanomaYIN Yue, QIU Xin-ye, ZHAO Zhi-gang, ZHANG Yan-hua1068-1072 